128 related articles for article (PubMed ID: 37838563)
1. Pharmacoeconomic issues in stem cell mobilization.
Lazzaro C
Transfus Apher Sci; 2023 Dec; 62(6):103829. PubMed ID: 37838563
[TBL] [Abstract][Full Text] [Related]
2. Pharmacoeconomic impact of up-front use of plerixafor for autologous stem cell mobilization in patients with multiple myeloma.
Kim SS; Renteria AS; Steinberg A; Banoff K; Isola L
Cytotherapy; 2014 Nov; 16(11):1584-1589. PubMed ID: 24927717
[TBL] [Abstract][Full Text] [Related]
3. Plerixafor: A chemokine receptor-4 antagonist for mobilization of hematopoietic stem cells for transplantation after high-dose chemotherapy for non-Hodgkin's lymphoma or multiple myeloma.
Steinberg M; Silva M
Clin Ther; 2010 May; 32(5):821-43. PubMed ID: 20685493
[TBL] [Abstract][Full Text] [Related]
4. Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.
Russell N; Douglas K; Ho AD; Mohty M; Carlson K; Ossenkoppele GJ; Milone G; Pareja MO; Shaheen D; Willemsen A; Whitaker N; Chabannon C
Haematologica; 2013 Feb; 98(2):172-8. PubMed ID: 22983579
[TBL] [Abstract][Full Text] [Related]
5. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N
Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-based versus chemotherapy-free stem cell mobilization (± plerixafor) in multiple myeloma patients: an Italian cost-effectiveness analysis.
Lazzaro C; Castagna L; Lanza F; Laszlo D; Milone G; Pierelli L; Saccardi R
Bone Marrow Transplant; 2021 Aug; 56(8):1876-1887. PubMed ID: 33753907
[TBL] [Abstract][Full Text] [Related]
7. Plerixafor strategies for autologous hematopoietic cell transplant mobilization: A comparison of efficacy and cost.
Chen KY; Bucci TG; Shaw JR; Alexander MD; Grgic T; Riches M; Ptachcinski JR
Transfus Apher Sci; 2022 Apr; 61(2):103303. PubMed ID: 34801430
[TBL] [Abstract][Full Text] [Related]
8. Plerixafor plus granulocyte colony-stimulating factor versus placebo plus granulocyte colony-stimulating factor for mobilization of CD34(+) hematopoietic stem cells in patients with multiple myeloma and low peripheral blood CD34(+) cell count: results of a subset analysis of a randomized trial.
Nademanee AP; DiPersio JF; Maziarz RT; Stadtmauer EA; Micallef IN; Stiff PJ; Hsu FJ; Bridger G; Bolwell BJ
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1564-72. PubMed ID: 22683613
[TBL] [Abstract][Full Text] [Related]
9. Stem Cell Mobilization Yields with Daratumumab- and Lenalidomide-Containing Quadruplet Induction Therapy in Newly Diagnosed Multiple Myeloma: Findings from the MASTER and GRIFFIN Trials.
Chhabra S; Callander N; Watts NL; Costa LJ; Thapa B; Kaufman JL; Laubach J; Sborov DW; Reeves B; Rodriguez C; Chari A; Silbermann R; Anderson LD; Bal S; Dhakal B; Nathwani N; Shah N; Medvedova E; Bumma N; Holstein SA; Costello C; Jakubowiak A; Wildes TM; Schmidt T; Orlowski RZ; Shain KH; Cowan AJ; Dholaria B; Cornell RF; Jerkins JH; Pei H; Cortoos A; Patel S; Lin TS; Usmani SZ; Richardson PG; Voorhees PM
Transplant Cell Ther; 2023 Mar; 29(3):174.e1-174.e10. PubMed ID: 36494017
[TBL] [Abstract][Full Text] [Related]
10. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M; Burns LJ; Barker JN; Miller JS; Defor TE; Olujohungbe AB; Weisdorf DJ
Biol Blood Marrow Transplant; 2004 Jun; 10(6):395-404. PubMed ID: 15148493
[TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of plerixafor addition in the mobilization and leukapheresis of hematopoietic stem cells for autologous transplantation: a systematic review.
Mesquita Augusto Passos R; Feldens TK; Marcolino MAZ; Gouvêa AS; Dos Santos Oliveira L; Menardi Nasser L; Rodrigues RF; de Lourdes Martins Perobelli L; Campolina AG; de Almeida Neto C
Expert Rev Pharmacoecon Outcomes Res; 2023 Jan; 23(1):15-28. PubMed ID: 36285481
[TBL] [Abstract][Full Text] [Related]
12. Cost analysis of a randomized stem cell mobilization study in multiple myeloma.
Varmavuo V; Silvennoinen R; Anttila P; Säily M; Sankelo M; Putkonen M; Ahonen J; Mahlamäki E; Mäntymaa P; Savolainen ER; Remes K; Jantunen E
Ann Hematol; 2016 Oct; 95(10):1653-9. PubMed ID: 27485453
[TBL] [Abstract][Full Text] [Related]
13. Long-term safety of the stem cell releasing compound plerixafor for peripheral stem cell collection in myeloma patients.
Maechler M; Bacher U; Daskalakis M; Nilius H; Nagler M; Taleghani BM; Jeker B; Pabst T
Hematol Oncol; 2023 Aug; 41(3):583-586. PubMed ID: 35920140
[No Abstract] [Full Text] [Related]
14. [Mobilization of peripheral blood stem cells with plerixafor in poor mobilizer patients].
Sancho JM; Duarte R; Medina L; Querol S; Marín P; Sureda A;
Med Clin (Barc); 2016 Sep; 147(5):223.e1-223.e7. PubMed ID: 27374031
[TBL] [Abstract][Full Text] [Related]
15. Plerixafor: a review of its use in stem-cell mobilization in patients with lymphoma or multiple myeloma.
Keating GM
Drugs; 2011 Aug; 71(12):1623-47. PubMed ID: 21861545
[TBL] [Abstract][Full Text] [Related]
16. Plerixafor as first- and second-line strategies for autologous stem cell mobilization in patients with non-Hodgkin's lymphoma or multiple myeloma.
Lor KW; Helmons PJ; Belew H; Lane JR; Ball ED
Pharmacotherapy; 2012 Jul; 32(7):596-603. PubMed ID: 22760691
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of hematopoietic stem cell mobilization strategies including plerixafor in multiple myeloma and lymphoma patients.
Tichopád A; Vítová V; Kořístek Z; Lysák D
J Clin Apher; 2013 Dec; 28(6):395-403. PubMed ID: 23922227
[TBL] [Abstract][Full Text] [Related]
18. Are we choosing mobilization regimens for autologous stem cell transplantation in multiple myeloma wisely: A single center comparison of GCSF+/-plerixafor vs cyclophosphamide/GCSF+/-plerixafor.
Yang C; Dehghani M; Hopman W; Bhella S
J Clin Apher; 2022 Aug; 37(4):348-353. PubMed ID: 35218068
[TBL] [Abstract][Full Text] [Related]
19. Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience.
Thurlapati A; Roubal K; Davis JA; Shah SZ; Smith D; McGann M; Gaffney K; Cendagorta A; Maldonado A; Weeda E; Hashmi H
Transplant Cell Ther; 2023 May; 29(5):340.e1-340.e4. PubMed ID: 36804934
[TBL] [Abstract][Full Text] [Related]
20. Hematopoietic Progenitor Cell Mobilization for Autologous Stem Cell Transplantation in Multiple Myeloma in Contemporary Era.
Arora S; Majhail NS; Liu H
Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):200-205. PubMed ID: 30679106
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
